Rintatolimod

Generic Name: Rintatolimod

Drug Type: Biotech

CAS Number: 38640-92-5

Unique Ingredient Identifier: 94325AJ25N

Clinical Trials

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

Phase 1

Recruiting

Conditions: Metastatic Pancreatic Cancer

Interventions: Biological: Durvalumab
Drug: Rintatolimod

First Posted Date: 2023-07-03

Last Posted Date: 2025-02-25

Lead Sponsor: Joachim Aerts, MD PhD

Target Recruit Count: 43

Registration Number: NCT05927142

Locations: 🇳🇱
Erasmus MC, Rotterdam, Zuid-Holland, Netherlands

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Phase 1

Active, not recruiting

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Unresectable Triple-Negative Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Biopsy
Drug: Celecoxib
Procedure: Computed Tomography
Biological: Interferon Alpha-2
Procedure: Magnetic Resonance Imaging
Drug: Rintatolimod
Biological: Pembrolizumab

First Posted Date: 2023-03-06

Last Posted Date: 2025-04-27

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 5

Registration Number: NCT05756166

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

Phase 2

Completed

Conditions: Long COVID
Post COVID-19 Condition

Interventions: Other: Placebo / Normal Saline
Drug: Rintatolimod

First Posted Date: 2022-10-24

Last Posted Date: 2025-01-22

Lead Sponsor: AIM ImmunoTech Inc.

Target Recruit Count: 80

Registration Number: NCT05592418

Locations: 🇺🇸
Acclaim Clinical Research, San Diego, California, United States
🇺🇸
Zenos Clinical Research, Dallas, Texas, United States
🇺🇸
Alfa Medical Research, Davie, Florida, United States

and more 2 locations

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Phase 2

Suspended

Conditions: Pancreatic Cancer

Interventions: Drug: Rintatolimod

First Posted Date: 2022-08-10

Last Posted Date: 2025-04-17

Lead Sponsor: AIM ImmunoTech Inc.

Target Recruit Count: 90

Registration Number: NCT05494697

Locations: 🇺🇸
Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Phase 1

Suspended

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Symptomatic COVID-19 Infection Laboratory-Confirmed

Interventions: Other: Best Practice
Biological: Recombinant Interferon Alfa-2b
Drug: Rintatolimod

First Posted Date: 2020-05-07

Last Posted Date: 2023-03-06

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 64

Registration Number: NCT04379518

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

Phase 2

Withdrawn

Conditions: Microsatellite Stable
Mismatch Repair Proficient
Stage IIIB Colorectal Cancer AJCC v8
Stage IIIC Colorectal Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Stage IVA Colorectal Cancer AJCC v8
Stage IVB Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8
Stage III Colorectal Cancer AJCC v8
Refractory Colorectal Adenocarcinoma

Interventions: Biological: Pembrolizumab
Other: Questionnaire Administration
Drug: Rintatolimod

First Posted Date: 2019-10-08

Last Posted Date: 2022-02-08

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT04119830

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Phase 2

Active, not recruiting

Conditions: HLA-A2 Positive Cells Present
Refractory Melanoma

Interventions: Biological: Alpha-type-1 Polarized Dendritic Cells
Drug: Celecoxib
Drug: PD-1 Ligand Inhibitor
Drug: PD1 Inhibitor
Biological: Recombinant Interferon Alfa-2b
Drug: Rintatolimod

First Posted Date: 2019-09-18

Last Posted Date: 2025-05-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 1

Registration Number: NCT04093323

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Phase 1

Completed

Conditions: HER2/Neu Negative
Progesterone Receptor Negative
Prognostic Stage IB Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Prognostic Stage II Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Triple-Negative Breast Carcinoma
Anatomic Stage IIA Breast Cancer AJCC v8

Interventions: Drug: Celecoxib
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Doxorubicin Hydrochloride
Drug: Paclitaxel
Biological: Recombinant Interferon Alfa-2b
Drug: Rintatolimod

First Posted Date: 2019-09-09

Last Posted Date: 2023-09-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 9

Registration Number: NCT04081389

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Phase 2

Recruiting

Conditions: Prostate Adenocarcinoma
Stage II Prostate Cancer AJCC v8
Stage IIA Prostate Cancer AJCC v8
Stage IIIA Prostate Cancer AJCC v8
Stage IIIC Prostate Cancer AJCC v8
Stage I Prostate Cancer AJCC v8
Stage IIC Prostate Cancer AJCC v8
Stage IIB Prostate Cancer AJCC v8
Stage III Prostate Cancer AJCC v8
Stage IIIB Prostate Cancer AJCC v8

Interventions: Drug: EC Aspirin
Procedure: Radical Prostatectomy
Biological: Recombinant Interferon Alfa-2b
Drug: Rintatolimod

First Posted Date: 2019-04-02

Last Posted Date: 2025-04-17

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 30

Registration Number: NCT03899987

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Phase 1

Recruiting

Conditions: Ovarian Cancer Recurrent

Interventions: Drug: Rintatolimod
Drug: Pembrolizumab
Drug: Cisplatin

First Posted Date: 2018-11-08

Last Posted Date: 2024-06-05

Lead Sponsor: Robert Edwards

Target Recruit Count: 45

Registration Number: NCT03734692

Locations: 🇺🇸
Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy